Войти в систему Зарегистрироваться бесплатно

Æterna Zentaris Институциональная собственность

Что обозначает Институциональная собственность в Æterna Zentaris?

Институциональная собственность Æterna Zentaris, Inc. является 1.23%

Какое определение для Институциональная собственность?



Институциональная собственность - это количество доступных акций компании, принадлежащих паевым или пенсионным фондам, страховым компаниям, инвестиционным фирмам, фондам или другим крупным организациям, которые управляют фондами от имени других.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Институциональная собственность компаний в Health Care сектор на TSX по сравнению с Æterna Zentaris

Что делает Æterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Компании с институциональная собственность похож на Æterna Zentaris